Skip to main content

Table 2 Disease symptoms and signs

From: Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

 

Interventional cohort

Observational cohort

P-value

N

n (%)

N

n (%)

Fever

98

77 (78.6%)

203

158 (77.8%)

0.99

Respiratory symptoms

98

80 (81.6%)

203

160 (78.8%)

0.65

Radiological evidence of pneumonia

98

97 (99.0%)

203

201 (99.0%)

0.99

Respiratory rate > 30

98

5 (5.1%)

203

7 (3.4%)

0.54

Oxygen saturation < 93%

98

34 (34.7%)

203

72 (35.5%)

0.99

PaO2/FiO2 < 300

98

33 (33.7%)

203

98 (48.3%)

0.02

Respiratory failure requiring invasive ventilation

98

0 (0.0%)

203

2 (1.0%)

0.99

Septic shock

98

0 (0.0%)

203

0 (0.0%)

n/a

Multiorgan failure

98

0 (0.0%)

203

0 (0.0%)

n/a

Fever > 38.3 °C

98

41 (41.8%)

203

64 (31.5%)

0.09

Cough

98

61 (62.2%)

203

109 (53.7%)

0.17

Dyspnoea

98

43 (43.9%)

203

106 (52.2%)

0.18

Fatigue

98

40 (40.8%)

203

78 (38.4%)

0.71

Myalgia

98

31 (31.6%)

203

25 (12.3%)

 < 0.001

Anosmia/Ageusia

98

24 (24.5%)

203

13 (6.4%)

 < 0.001

Nausea/Vomiting

98

9 (9.2%)

203

16 (7.9%)

0.82

Diarrhoea

98

18 (18.4%)

203

30 (14.8%)

0.50

Conjunctivitis

98

3 (3.1%)

203

3 (1.5%)

0.40

Confusion

98

4 (4.1%)

203

18 (8.9%)

0.16

Headache

98

17 (17.3%)

203

15 (7.4%)

0.02